Wutah pendapatan taun lumaku: Nuvation Corp (NUVB)

Logo perusahaan publik nuvationbio.com (NUVB)

The high barrier to entry in the oncology business, driven by colossal costs and patent protection, makes Nuvation Bio Inc. (NUVB) a promising asset. The year-over-year revenue change over the trailing twelve months (TTM) visualizes this potential, where 656.00 shows the value of this parameter. Flexible raw material supply chains ensure stability, while investor confidence is bolstered by the effective merger of new biotechnological units under management control.

Nuvation Bio Inc. (NUVB): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Nuvation Bio Inc. - rincian analitis lan metrik utama (NUVB)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Nuvation Pharma
Produk merek Nuvation Corp

To objectively evaluate Nuvation Bio Inc. (NUVB), a manager requires an analysis of trailing twelve-month revenue dynamics, measuring the daily rate of change in operating income to determine the stability of the business trajectory. By analyzing the year-over-year revenue growth trend over a rolling year, an investor can identify risks of slowing expansion caused by geopolitical disruptions in component supplies or complexities regarding international patent protection.

Karo sapa Nuvation Bio Inc. saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Day One|MNPR: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Inhibrx Biosciences Inc INBX|Wutah pendapatan YoY sajrone 12 wulan kepungkur IMAB|Wutah pendapatan taun lumaku Fennec Pharmaceuticals FENC|Wutah pendapatan YoY sajrone 12 wulan kepungkur HRTX (Heron)|NVCT (Nuvectis Pharma) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Coherus Biosciences - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur BYSI (BeyondSpring Pharma)|BCAB: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku lixte.com (LIXT)|Wutah dodolan YoY sajrone rolas wulan kepungkur citiuspharma.com|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur